TGFb-activated kinase 1 binding protein 1 (TAB1) during myocardial ischemia and other stresses. Chemical-genetic approaches and coexpression in mammalian, bacterial and cell-free systems revealed that mouse p38a autophosphorylation occurs in cis by direct interaction with TAB1(371-416). In isolated rat cardiac myocytes and perfused mouse hearts, TAT-TAB1(371-416) rapidly activates p38 and profoundly perturbs function. Crystal structures and characterization in solution revealed a bipartite docking site for TAB1 in the p38a C-terminal kinase lobe. TAB1 binding stabilizes active p38a and induces rearrangements within the activation segment by helical extension of the Thr-Gly-Tyr motif, allowing autophosphorylation in cis. Interference with p38a recognition by TAB1 abolishes its cardiac toxicity. Such intervention could potentially circumvent the drawbacks of clinical pharmacological inhibitors of p38 catalytic activity. npg
a r t i c l e s The p38 mitogen-activated protein (MAP) kinase family (p38) comprises four isoforms; α, β, γ and δ (ref. 1). Among these isoforms, α is ubiquitously expressed and most widely studied. Furthermore, p38α is essential for normal development 2 , whereas the absence of the other isoforms 3 , even in combination, results in a normal or near-normal adult phenotype. Owing to the central role of p38α in regulating the immune response, inhibitors of p38α and p38β kinase activity were among the first relatively selective kinase inhibitors to be developed 4 , understood at the atomic level 5 and clinically tested 6 in the treatment of inflammatory diseases. Although numerous inhibitors with diverse structures and binding modes have been developed, none has progressed beyond phase II clinical trials 6, 7 . The amount of information in the public domain that would explain the failure of these inhibitors in the clinic is limited, but it seems very likely that this failure is the result of liver and skin toxicity as well as the appearance of bypass or escape mechanisms 7, 8 . These same drawbacks are common to diverse inhibitors with different modes of binding to the p38α active site, thus suggesting a class effect. For this reason, it has been suggested that alternative strategies targeting p38α are needed 8 .
Studies with kinase inhibitors and genetic manipulation have provided overwhelming evidence that the activation of p38α that accompanies lethal myocardial ischemia aggravates injury 9 . During myocardial ischemia, the activation of p38 is unusual in that catalytic inhibitors prevent the phosphorylation of the Thr-Gly-Tyr (TGY) motif within the activation loop 9, 10 . In subsequent studies, this observation was shown to be the result of the likely autophosphorylation initiated by the binding of p38α to the scaffold protein, TGF-β-activated protein kinase 1 (TAK1) binding protein 1 (TAB1) [10] [11] [12] [13] [14] . TAB1 was instrumental in the first described signaling pathway by which p38α becomes activated independently of its usual archetypal, canonical upstream MAP kinase kinases (MAPKKs) 15 . Furthermore, TAB1 phosphorylation by p38 diminishes its ability to activate TAK1, thus closing a feedback loop 16 . Subsequently, other circumstances enabling p38α autophosphorylation have been described 17, 18 . Nonetheless, the idea of p38α activation by autophosphorylation remains controversial because there are a number of conceptual obstacles that must be overcome 19 . In canonical MAP-kinase signaling, p38α is activated by the transphosphorylation of the TGY motif by the MAPKKs. This event causes the activation loop to clear the substrate-binding cleft and results in the reorientation of the N-and C-terminal lobes needed to bring Lys53, Glu71 and Asp168 into the necessary alignment to coordinate ATP binding 20 . The macroscopic consequence is a marked increase in the binding affinity of p38α toward ATP 21 . Thus, ATP binding follows TGY-motif transphosphorylation. However, for autophosphorylation to occur ATP binding needs to precede TGY phosphorylation, and this requires the prior alignment of residues for high-affinity ATP interaction. This circuitous paradox has been aptly likened to a 'Catch-22' and is relevant to at least four other mammalian kinases 19, 22 .
Because the TAB1-initiated form of p38α activation has been shown by numerous independent groups to aggravate myocardial injury [10] [11] [12] [13] [14] , it may be therapeutically relevant. Moreover, therapies that exploit this relatively unusual mechanism of p38 activation could avoid the drawbacks seen with inhibitors of p38 catalytic activity because the observed toxicity is likely to be unrelated to this restricted mechanism of activation 7, 8 . For these reasons, the purpose of our study was to elucidate the molecular mechanisms that lead to TAB1-induced, MAPKK-independent p38α autoactivation during myocardial ischemia.
RESULTS p38a is activated by autophosphorylation during ischemia
In the past, we and others have shown p38 and TAB1 coassociate during myocardial ischemia [10] [11] [12] [13] and that dual phosphorylation of p38's TGY activation motif is sensitive to p38 inhibitors that do not inhibit the immediately upstream MAPKKs 10, 23 . The most likely explanation for these observations is TAB1-initiated p38 autophosphorylation 9, 15, 23, 24 . However, phosphorylated TGY, which is monitored as a readout of autophosphorylation, is common to all p38 isoforms, and it is therefore uncertain which specific isoform contributes to the reduction in signal intensity as a result of p38 kinase inhibition. Type I ATP-competitive kinase inhibitors affect both p38α and p38β because they share a small threonine gatekeeper residue 5, 20 . In p38γ and p38δ, this residue is a larger methionine, which is responsible for their resistance to inhibition 5 . Thus the autophosphorylation signal must arise from p38α and/or p38β.
Recently we have adopted a chemical-genetic approach using mice in which either both p38α (ref. 24) or both p38β (ref. 25 ) alleles carried a T106M gatekeeper substitution allowing selective targeting of each of these two isoforms. Here we use this system to examine the relative contribution of p38α and p38β to p38 autoactivation and to determine whether transphosphorylation by upstream kinases can ultimately compensate for the block in autophosphorylation during early ischemia. Figure 1a demonstrates the pattern of p38 dual phosphorylation during global myocardial ischemia. In wild-type (WT) hearts, ischemia initiated p38 dual phosphorylation that is sensitive to the p38α and p38β inhibitor SB203580. In hearts expressing the p38α T106M gatekeeper mutant that does not bind SB203580 (IRp38α), p38 remained active, as determined by phosphorylation of the direct downstream substrate TAB1 and the indirect downstream substrate HSP27. In hearts in which p38β is resistant to SB203580 (IRp38β), the dual autophosphorylation of p38 and phosphorylation of its downstream substrates was inhibited by SB203580. These patterns were similar at 5, 10 and 15 min of ischemia. In combination with our previous observations 24, 25 , the findings confirm that (i) p38α is the dominant isoform activated during myocardial ischemia by a mechanism Fig. 1a , comparison of IRp38α to WT at 10 and 15 min); and (iii) if the autoactivation of p38α can be prevented, myocardial total p38 activity will remain low. The question remains, however, whether this signature is consistent with TAB1-mediated p38 phosphorylation. We addressed this issue by the following experiments. We coexpressed TAB1 and WTp38α or IRp38α in HEK293 cells ( Fig. 1b) . TAB1 enhanced p38α dual phosphorylation in an SB203580-sensitive manner, akin to the observation in WT hearts ( Fig. 1a) . Moreover, this pattern was lost when the IRp38α was coexpressed with TAB1, a result once again consistent with our previous observations ( Fig. 1a) . Finally, this pattern was altered when cells were exposed to BIRB796, a type II p38α and p38β inhibitor that does not depend on Thr106 for binding ( Fig. 1c) . Once again, this pattern was identical to that seen in hearts expressing IRp38α (ref. 24 ). However, one complication in interpreting coexpression data in eukaryotic cells is that TAB1 also promotes the autoactivation of TAK1, a kinase that lies upstream of p38 (ref. 16) . To exclude such a scenario, in which TAB1-initiated transphosphorylation masquerades as autophosphorylation, we repeated these coexpression experiments in Escherichia coli, a background that is devoid of almost all protein kinases ( Fig. 1d) . These experiments demonstrated that p38α phosphorylation was enhanced by TAB1 coexpression and diminished by pharmacological inhibitors of p38 catalytic activity. Moreover, the effect of TAB1 persisted for C-terminal truncations containing the TAK1-interacting domain 26 . The recapitulation in E. coli of TAB1initiated p38α activation encouraged us to purify the individual proteins, map the interacting regions in both proteins and examine the biophysical characteristics of their interaction.
TAB1(371-416) interacts with p38a, increasing ATP affinity
The outcome of the p38α-TAB1 coexpression experiments in E. coli (Fig. 1d ) suggests a direct interaction between the two proteins. To test this hypothesis, we used isothermal titration calorimetry (ITC). However, the inherent instability of full-length TAB1, when produced and purified from E. coli, prevented its use in these experiments; instead, we choose TAB1(1-438) as a positive control because it is known to encompass the entire region responsible for p38α autoactivation 15, 26, 27 (Fig. 1c) while still incorporating the portion that acts as a p38α substrate (Ser423 and Thr431) 16 .
ITC experiments confirmed a direct interaction between TAB1 (1-438) and p38α, revealing a monophasic 1:1 binding isotherm and a binding affinity in the low-micromolar range in the experimental conditions used ( Fig. 2a and Table 1 ). From an analysis of previously published characterizations 15, 27 , we identified a 46-residue region of TAB1, TAB(371-416), which had similar ITC binding characteristics to TAB(1-438). On the basis of these data and that the peptide is necessary and sufficient for TAB1-mediated activation of p38, we hypothesize that this short polypeptide contains the residues required for TAB1 recognition. Furthermore, the thermodynamics of binding observed in these experiments are compatible with some structural rearrangement upon TAB1-p38α interaction (described below).
Next, we examined whether TAB1, and in particular the shorter TAB1(371-416), could overcome the key conundrum underlying the Catch-22 paradox. As discussed above, during MAPK-independent autophosphorylation, ATP binding must necessarily precede activationloop phosphorylation. We therefore asked whether TAB1 binding switches p38α from its inactive low-affinity ATP state to a high-affinity ATP state competent for autophosphorylation. The titration of the nonhydrolyzable (hence stable) ATP-γS into p38α alone generated no measurable association by ITC ( Fig. 2b) , a result suggesting that, owing to low affinity, no heat is detected. This is in agreement with previous results 21 . However, under identical conditions, after addition of ATP-γS to a solution of p38α in the presence of TAB1(1-438), we observed a well-interpolated sigmoid curve based on an independent and equivalent binding-sites model centered on a 1:1 stoichiometry. This is indicative of a p38α-ATP association with a low-micromolar affinity ( Fig. 2b and Table 1 ). An overall comparison of thermodynamic signatures of interactions ( Fig. 2 and Table 1 ) suggests that the shorter TAB1 fragment contains the main determinants for association with unphosphorylated or inactive p38α and enables consequent marked enhancement of its ability to bind ATP Figure 2 Thermodynamic characterization of TAB1-p38α complex formation on ATP affinity and autophosphorylation in cis. (a) ITC analysis of the interaction between p38α and TAB1. (b) ITC analysis of the interaction between p38α and ATP-γS. Titration of a solution of ATP-γS into p38α in the presence or absence of TAB1 . Raw data of the titration of ATP-γS into p38α alone were displaced by +0.02 µcal/s for clarity. For a and b, all but the first points were used for curve fitting; derived thermodynamic parameters are shown in Table 1 . a r t i c l e s in a manner reminiscent of that observed upon dual phosphorylation of the TGY motif 21 . However, to ensure that the effect observed in these experiments was indeed linked to the specific binding of ATP in the p38α nucleotide-binding pocket, we performed analogous ITC experiments using SB203580, an ATP-competitive inhibitor that, unlike ATP, is known to have equal affinity for the active and inactive conformation of p38α (refs. 5,20) . The interaction of SB203580 with p38α was found not to be appreciably affected by the presence of TAB1(1-438) or TAB1(371-416) ( Supplementary Fig. 1 and Table 1 ). Taken together, our ITC experiments point toward a model in which TAB1 binds p38α and increases its affinity for ATP. 
Values reported are averaged over three experiments; errors are <5%. Nonphospho-p38α binding affinity to ATP is below the threshold that could be measured by ITC; the value reported was obtained with time-resolved FRET (TR-FRET, described in ref. 21 ). All measurements were performed at 25 °C except p38α-TAB1(1-438) complex-ATP-γS, which was run at 10 °C. ND, not detectable by ITC. n, molar ratio between the two species in the syringe and calorimetric cell, respectively. Supplementary Table 1 ). Gray, unassigned residues; light blue, residues for which the assignment is available; orange, residues that show an average chemical-shift perturbation (∆δ AV ) >0.05; yellow, residues with ∆δ AV <0.05; gold, residues that disappear in the course of the NMR titration. Asterisk denotes Ile275, defined as a point of contact in b. (b) Signals extracted from a 15 N-13 C-filtered NOESY experiment acquired on a p38α-TAB1(371-416) complex. p38 was perdeuterated and 15 N and 13 C labeled, and TAB1 was unlabeled. Asterisk denotes unassigned residue as point of contact. (c) Structural overview of p38α-TAB1(384-412). TAB1 is shown as yellow sticks on the surface of p38α, represented as surface electrostatic potential between −10 kT/e (red) and +10 kT/e (blue). Ø A and Ø B indicate surface interacting with canonical motifs within binding partners (as illustrated in Supplementary Fig. 4b 
TAB1 accelerates p38a autophosphorylation in cis
To test the biochemical consequences of the binding of TAB1 to p38α and the binding of ATP to this complex, we performed in vitro kinase assays with the dual phosphorylation of the TGY activation motif of p38α as the readout of autophosphorylation. The presence of the 46-mer TAB1(371-416) greatly accelerated the autophosphorylation of p38α ( Fig. 2c) . It is unclear whether this event is intramolecular (autophosphorylation in cis) or due to the activation loop of one p38α molecule entering the substrate-binding cleft of another (autophosphorylation in trans through activation-loop exchange) 28 . To address this question, we performed two complementary experiments. First, we used an in vitro kinase assay using the recombinant purified p38α in WT form and in kinase-dead (KD) form (K53M) (Fig. 2d) . The KDp38α was unable to undergo TAB1-initiated autophosphorylation. This deficit was apparent when KDp38α was present either in isolation or together with WTp38α. One possible explanation for the inability of KDp38α to autophosphorylate relates to the complex effect that such mutations, on the ATP-binding interface between N-and C-terminal lobes, have on the fold of a kinase 29 . For this reason, we repeated the experiment, using an analog-sensitive (ASK) form of p38α engineered to accept an expanded form of ATP (characterization in Fig. 2e ) 30 . In this case, WTp38α rather than KDp38α acted as the probe for the presence of autophosphorylation in trans. Despite WTp38α being capable of autophosphorylation, there was a minimal signal when an expanded form of ATP was present as the phosphate donor ( Fig. 2f) . In this case, the autophosphorylation was mainly limited to ASKp38α. Finally, to examine the possibility that nucleotide binding is a prerequisite for autophosphorylation in trans, we performed additional autophosphorylation experiments ( Supplementary Fig. 2) . In combination, these complementary experiments indicate that the binding of TAB1(371-416) to p38α greatly accelerates the autophosphorylation of its activation loop and that this event occurs in cis, as previously suggested 15 . We next attempted to characterize the rearrangements within p38α that enable autophosphorylation and the residues in TAB1 and p38α responsible for mutual recognition.
NMR analyses of p38a, showing TAB1(371-416) interaction
We used NMR to map the interaction surfaces between p38α and TAB1. In particular, we investigated the chemical-shift perturbations experienced by p38α amide groups in a 2 H-15 N-labeled sample upon titration of unlabeled TAB1(371-416) ( Supplementary  Fig. 3a) . The chemical-shift variation analysis identified several affected regions in p38α; these were spread over the entire C-terminal lobe, and this could be indicative of long-range conformational rearrangements upon peptide binding ( Supplementary  Table 1 and Fig. 3a) .
The chemical-shift mapping alone is, however, unable to discriminate between regions responsible for direct proteinpeptide contact and regions that undergo conformational rearrangement upon binding. To better define the direct points of contact between p38α and TAB1 peptide, we performed 15 N-13 Cfiltered NOESY experiments on perdeuterated, 15 N-13 C-labeled p38α and unlabeled TAB1 peptide. The combination of the labeling scheme with the appropriate NMR filter experiment (Online Methods) enabled the selective detection of NOE signals arising from protons bound to 12 C and 14 N (i.e., TAB1) to protons bound to 15 N (i.e., p38α amide protons). Each strip (Fig. 3b) showed a point of contact between TAB1 protons and p38α amides. Ile275, located on the C lobe of p38α, was clearly identified to interact directly with TAB1, on the basis of unambiguous NOE signals from its amide proton to resonances at 0.8 and 1.9 p.p.m. Although three more NH resonances of p38α exhibited detectable NOE contacts with TAB1 protons, the responsible residues could not be unequivocally assigned, and this prompted a complementary structural analysis.
Guided by the NMR experiments ( Supplementary Fig. 3a,b) , we ultimately used a peptide corresponding to TAB1(384-412) for crystallization trials. We confirmed that this shorter 29-mer peptide recapitulated the effects of the 46-mer (TAB1(371-416)) peptide to accelerate p38α autophosphorylation in vitro ( Supplementary  Fig. 3c ) and also in terms of the thermodynamic signature of its interaction with p38α by ITC (Supplementary Table 2 and Supplementary Fig. 3d ).
Crystal structure of the p38a-TAB1(384-412) complex
Complexes of TAB1(384-412) with p38α crystallized in two forms ( Table 2) , and the electron density in all three structures revealed two distinct patches, thus suggesting that TAB1 binds the C lobe of p38α in a bipartite manner ( Fig. 3c and  Supplementary Fig. 4) . The C-terminal region of the TAB1 peptide bound within the groove defined by α D and α E helices and the reverse turn between β 7 and β 8 (canonical upper site or ED domain) ( Fig. 3c,d ) while its N terminus bound a lower hydrophobic pocket created by α F and α H helices and the loop connecting helix α 2L14 to helix α H (noncanonical lower site) (Fig. 3c,d) . The intervening nine residues of the peptide, between these two interaction sites, were not visible in the crystal structures. The canonical upper site of the p38α-TAB1 complex overlaps with the binding surface used by other proteins that interact with MAPKs through canonical docking motifs, such as p38α-MKK3b, p38α-MEF2a, JNK1-JIP1 and ERK2-HePTP npg a r t i c l e s ( Supplementary Fig. 4b) . The surface defined by the noncanonical lower site appears specific to the p38α-TAB1 interaction and was not identified in currently available structures of MAPKs in complex with binding partners.
TAB1(384-412) configures p38a for autophosphorylation
The rearrangements induced by TAB1 binding are highlighted through comparison with uncomplexed p38α (ref. 31 ) and indicate the basis of the increased ATP binding affinity ( Fig. 2b) and propensity for autophosphorylation in cis ( Fig. 2c-f) .
The accommodation of TAB1 at the boundaries of helices α D , α E and α F and sheets β 7 and β 8 was associated with displacements parallel to their long axes (Fig. 4a) . These changes, local to the TAB1-binding site, were accompanied by more marked distant rearrangements, perhaps reflecting networks of connectivity that are anchored to α F (ref. 32 ).
Most strikingly, the N and C lobes of the kinase are brought into proximity and undergo closure most usually associated with phosphorylation of the activation segment ( Fig. 4b) . Furthermore, within the N lobe there was an inward swing of α C that brought Glu71 within 2.7 Å of Lys53 and enabled formation of the salt bridge typical of an active kinase (Fig. 4b) 32 . It is expected that these changes within the nucleotide-binding pocket will increase affinity toward ATP.
Of particular interest is a long-range effect observed in the activation loop (Leu171-Val183) in which major conformational rearrangement occurred (Fig. 4c) . The loop contains the phosphorylation sites npg a r t i c l e s Thr180 and Tyr182 of the TGY motif, which in apo-p38α adopts an extended conformation with the side chains of both threonine and tyrosine residues pointing away from the catalytic site. Binding to TAB1 caused Tyr182-Thr185 to extend the short α-helical segment that was stabilized by an interaction between Thr185 and Asp150 of the HRD motif. This structural alteration displaced the TGY motif by ~10 Å and brought it toward the catalytic site, with the side chain of Thr180 in a favorable position for ATP γ-phosphate transfer (Fig. 4c) . The formation of the extended helical segment within the activation loop was present in all crystal forms and seems unique to the p38-TAB1 complex. It is therefore tempting to speculate that it represents a transition intermediate in the cis-autophosphorylation reaction.
Disrupting the p38a-TAB1 interaction
To assess the individual role of the two recognition sites in the p38-TAB1 complex, we prepared the following TAB1 variants, in which residues were mutated in pairs as follows: V390A Y392A (designated TAB1(371-416A), disrupting lower, noncanonical site), V408G M409A (designated TAB1(371-416B), disrupting upper, canonical site) and V390A Y392A V408G M409A (designated TAB1(371-416A-B), disrupting both sites). We used ITC to examine the binding behavior of these TAB1 mutants to p38α. We detected no binding with TAB1(371-416A-B), whereas the individual mutation pairs exhibited changes in the thermodynamic signature of binding but with a similar dissociation constant to that of WT TAB1 (Fig. 5a and Table 1 ). However, although the WT TAB1 interaction was enthalpically driven (with a negative entropic contribution), for TAB1(371-416A) and TAB1(371-416B) the interaction was entropically driven (with a smaller enthalpic contribution), a result reflecting differences in the interaction and/or its consequences. p38b lacks the noncanonical site for TAB1 interaction p38α and p38β are highly homologous and equally sensitive to pharmacological inhibition. Nonetheless, global ablation of p38α in mice results in early embryonic lethality, whereas there is barely a discernible phenotype when p38β is targeted 3 . In p38β, the upper canonical Supplementary Figure 6. a r t i c l e s TAB1-binding site is conserved, whereas the lower pocket is disrupted by bulky I275R and T218Q substitutions (Fig. 3d) . The ITC data of the interaction between p38β and TAB1 peptide confirm that the β isoform binds by using only the upper canonical site (Fig. 5b) . The thermodynamic signature of the binding between p38β and nonmutated TAB1 is reminiscent of that observed between p38α and the individually mutated forms of TAB1 (Table 1 and Fig. 5a) ; the functional consequence is that p38β is not similarly autoactivated by TAB1 (Supplementary Fig. 5a ). Furthermore, we have examined the importance of Ile275 (highlighted as a point of contact in Fig. 3b ) by its substitution in isolation within the p38α backbone. The autophosphorylation of p38α (I275G) by TAB1(371-416) is slower than that seen with WTp38α (Supplementary Fig. 5b) , and this is also reflected by a different thermodynamic signature of interaction (Supplementary Table 2 and Supplementary Fig. 3d ).
Effect of TAB1 mutations on myocardial p38 and function
Having confirmed there was a deficit in the binding of TAB1 (371-416A-B) to p38α, we next determined whether this was also accompanied by the loss of its ability to induce p38α autophosphorylation in vitro and in vivo. We found a marked difference between TAB1(371-416) and TAB1(371-416A-B) 46-mer peptides in their ability to accelerate p38α autophosphorylation in vitro, a result confirming the importance of the A and B residue pairs in the functional interaction (Fig. 5c) .
To examine the importance of these residue pairs in the context of the TAB1 protein backbone, we ectopically coexpressed p38α with TAB1(1-418), TAB1(1-418A), TAB1(1-418B) or TAB1(1-418A-B) in both prokaryotic (Fig. 5d) and eukaryotic (Fig. 5e) systems. The data show that each individual pair of mutations (A or B) is sufficient to diminish TAB1-induced autophosphorylation of p38α and that when present in combination (A and B), TGY-motif phosphorylation is reduced to that seen when p38α is expressed in isolation.
Finally, to determine the effect of the TAB1-mediated p38α interaction on the heart, we exposed isolated adult rat cardiac myocytes and perfused isolated mouse hearts to TAB1(371-416), TAB1(371-416A-B) or a scrambled form of the peptide TAB1(371-416SCR), each fused to a cell-penetration peptide derived from the HIV1 transactivator of transcription (TAT) (Fig. 6a) . Using fluorescein-labeled TAT-TAB1(371-416), we confirmed that the peptide penetrates cardiac myocytes in culture and in perfused isolated hearts (Fig. 6b) . In isolated cardiac myocytes, the peptide is widely distributed, with the greatest accumulation in nuclei and at intercalated discs (Fig. 6b) . TAB1(371-416) but not TAB1(371-416A-B) caused p38 activation ( Fig. 6c) and, at later time points, cell death (rounded appearance of cells with homogeneous distribution of fluorescein label). Similarly, in isolated perfused hearts TAT-TAB1(371-416) (Fig. 6d) , but not the other peptides, caused an elevation in the end-diastolic pressure and a marked reduction in developed pressure (Fig. 6e) . These changes were accompanied by a reduction in coronary flow (Fig. 6f) and by p38 dual phosphorylation (Fig. 6g) . Furthermore, these effects were reversed by pharmacological inhibition of p38 (Fig. 6h) . In combination, these data indicate that artificially driving the p38α-TAB1 association in myocardium has detrimental effects, thus suggesting that specific inhibition of the association documented during myocardial infarction 10, 12, 13 would be cardioprotective.
DISCUSSION
This study describes the molecular mechanism of TAB1-mediated p38α autophosphorylation. The salient findings are that (i) TAB1 interacts directly with p38α; (ii) this interaction increases the affinity of p38α toward ATP; (iii) as a consequence, p38α autophosphorylates its activation loop in cis; (iv) the ability to induce p38α autophosphorylation resides in residues 371-416 of TAB1; (v) TAB1 makes direct contact with p38α in a bipartite manner with occupancy of both sites required for optimal autophosphorylation; (vi) the TAB1-induced autoactivation mechanism is specific to p38α, thus sparing p38β; and (vii) the autoactivation of p38α through the TAB1 interaction can be artificially driven in isolated cardiac myocytes and perfused hearts, and it causes reduced viability and function.
The autophosphorylation of Thr180 and Tyr182 within the activation loop is conceptually difficult to accept: p38α is a serine/threonine kinase and should therefore have difficulty phosphorylating Tyr182. Nonetheless, there are at least four other examples in the literature of WT serine/threonine kinases autophosphorylating on a tyrosine, specifically DYRK, GSK3β, fus3 and PLK4 (refs. 19,22) . Fus3 is the only other kinase for which the molecular mechanism of autoactivation is understood at an atomic level 33 . Fus3 is a highly conserved p38 yeast homolog that is similarly activated by dual phosphorylation of its TGY activation motif by an upstream MAPKK. However, Bhattacharyya et al. have shown that it can also be activated and autophosphorylated after binding full-length Ste5, a scaffold protein, and such activity resides in a 28-residue region (encompassing 288-316) 33 (Fig. 4b and Supplementary Fig. 4b) . Cocrystallization of Fus3 with this peptide revealed an allosteric mechanism of activation in which Ste5 establishes contact points in both the N-and C-terminal lobes of Fus3, and this results in their reorientation to achieve kinase activity 33 . Nevertheless, despite many similarities, the Fus3-Ste5 and p38α-TAB1 systems use different molecular mechanisms to achieve autophosphorylation. First, our structural data show that the TAB1 peptide establishes contact points only with the C lobe of p38α. We also identify a new binding site on the kinase surface that at present is TAB1 specific. Moreover, in the Fus3-Ste5 system, the autophosphorylation is only of the tyrosine, whereas in the p38α-TAB1 system it is dual autophosphorylation.
The atomic details of the interaction of TAB1 with p38α presented here unambiguously show that TAB1 is capable of overcoming the Catch-22 paradox because its binding to p38α is accompanied by a dramatic increase in affinity of p38α toward ATP. At the molecular level, this is linked to distant conformational rearrangements of the ATP-binding site and of the activation loop.
The interaction of p38α and TAB1 is circumstance specific. Interestingly, all the circumstances reported in the literature so far are harmful to the cell, and this is particularly well illustrated by myocardial ischemia and infarction [10] [11] [12] [13] and cardiac amyloidosis 14 . p38α and TAB1 are ubiquitously expressed, and the residues involved in TAB1-p38α recognition are conserved across species, thus suggesting that the interaction may have broader relevance. However, tool compounds are needed to examine other contexts in which this interaction is important and to explore the utility of disrupting it in the context of myocardial infarction. Ultimately, such compounds may enable circumstance-specific p38α inhibition that circumvents the toxicity of pharmacological inhibitors and/or their lack of efficacy seen in recent clinical trials 7, 8 .
METhODS
Methods and any associated references are available in the online version of the paper.
Accession codes.
Coordinates and structural factors for p38α-TAB1 have been deposited in the Protein Data Bank under accession codes 4LOO, 4LOP and 4LOQ.
npg

ONLINE METhODS
Expression and purification of p38a, 2 H/ 15 N p38a and 2 H/ 13 C/ 15 N p38a. DNA encoding mouse p38α was derived from a pET14b vector kindly donated by Y. Wang 34 and subcloned into a pETDuet-1 vector. The full coding sequence included an N-terminal His 6 tag followed by a TEV-cleavage site and mouse p38α sequence. The vector was transformed in E. coli strain Rosetta II cells (Novagen). The protein expression and purification procedure followed is described in ref. 35 . For 2 H/ 15 N p38α, 1 l culture was grown in minimal medium containing 0.8 g/L 15 N -ammonium chloride and 95% D 2 O. For 2 H/ 13 C/ 15 N p38α, 1 l culture was grown with Silantes E. coli OD2 growth medium ( 13 C, 98%; 2 H, 98%; 15 N, 98%). For the labeled proteins, purification was performed as above. TAB1(1-438) . Chemically synthesized DNA encoding mouse TAB1 was subcloned into a pETDuet-1 vector. The full coding sequence included an N-terminal His 6 tag followed by a TEV-cleavage site and mouse TAB1 . The vector was transformed in E. coli strain Rosetta II cells. Recombinant TAB1(1-438) was expressed and purified according to the same protocols used for p38α.
Expression and purification of
TAB1(371-416).
The peptides corresponding to TAB1(371-416) and TAB1(384-412) were purchased from Activobiotech. Peptide for NMR study, purchased from Thermo Fisher, was selectively 15 N, 13 C labeled on the following residues: E( 15 N, 13 Cloning and coexpression of p38a and TAB1 constructs. pETDuet-1 vector was used for bacterial coexpression of p38α and the different TAB1 mutants (p38αK53M(KD), p38αI275G, p38α-TAB1(1-502), p38α-TAB1(1-438), p38α-TAB1(1-418), p38α-TAB1(1-418A V390A Y392A), p38-TAB1(1-418B V408G M409A) and p38-TAB1(1-418A-B V390A Y392A V408G M409A). In all the bacterial vectors, p38α was subcloned in the first multiple-cloning site, whereas TAB1 was subcloned in the second multiple-cloning site. All the TAB1 mutants were obtained with the same strategy: overlapping C-and N-terminus fragments were produced by PCR with complementary internal primers containing the desired mutations. The PCR products from this reaction were then combined to form the template for a second PCR reaction with external primers.
In vitro kinase assays and immunoblot analysis. Depending on the experiment, WTp38α, KDp38α, ASp38α, p38αI275G or an equimolar mixture of two (3 µM) were incubated with WT TAB1(371-416), TAB1(384-412) or mutated TAB1(371-416A-B) (15 µM) in buffer containing 100 mM NaCl, 20 mM Tris, pH 7.5, 2 mM DTT, 2 mM MgCl 2 and 600 µM ATP. The reactions were monitored for at least 2 h. Samples were resolved on a 10% reducing SDS-PAGE gel and blotted onto a polyvinylidene difluoride membrane. Membranes were incubated in Ponceau S solution (Sigma) for 5 min. After proteins had been visualized, membranes were rinsed in distilled water and destained in 0.1 M NaOH. Membranes were blocked for 1 h in 1.33% low-fat milk and 0.33% bovine serum albumin in Tris-buffered saline, pH 7.4, and 0.1% Tween-20. Primary antibodies were incubated overnight at 4 °C with agitation. Antibodies used included anti-dual-phosphorylated p38 (Thr180, Tyr182) (M8177, Sigma and 9211, Cell Signaling Technology) 1:4,000, Total p38 (9212, Cell Signaling Technology) 1:15,000, anti-phospho-p38 Tyr182 (sc-7975-R, Santa Cruz Biotechnology) 1:2,000. After washing and incubation with the appropriate HRP-conjugated secondary antibody (NA 943ML for rabbit primary and NA931ML for mouse primary, both from GE Healthcare and diluted 1:2,000, and 31480, ThermoScientific, for sheep primary at 1:1,000), antibodyantigen complexes were visualized by enhanced chemiluminescence (Pierce).
Original images of blots used in this study can be found in Supplementary  Figure 6 . All antibodies are validated for use to detect rodent protein on immunoblots (as shown on manufacturers' websites).
ITC titrations.
All ITC experiments were carried out on an iTC200 microcalorimeter from Microcal (GE Healthcare). SB203580 and ATP-γS were purchased from Tocris Bioscience at the highest purity available.
Heat produced by titrant dilution was verified to be negligible by a control experiment involving titration into buffer alone, under the same conditions. Integrated heat data obtained for the titrations corrected for heats of dilution were fitted with a nonlinear least-squares minimization algorithm to a theoretical titration curve, with MicroCal-Origin 7.0 package. ∆H° (reaction enthalpy change in kcal mol −1 ), K b (equilibrium binding constant in M −1 ) and n (molar ratio between the two species in the syringe and calorimetric cell, respectively) were the fitting parameters. The reaction entropy was calculated with the relationships ∆G = −RT×lnK b (R, 1.987 cal mol -1 K −1 , T, 298 K) and ∆G = ∆H − T∆S.
NMR spectroscopy. Spectra of free p38α and of p38α-TAB1(371-416) complex were acquired in buffer containing 50 mM NaCl, 20 mM Tris, pH 7.5, and 2 mM DTT, whereas those of TAB1(371-416) were acquired in buffer containing 20 mM Tris, pH 7.5, and 2 mM DTT. Sample concentrations of free p38α and free TAB1(371-416) were 0.5 mM. Samples of p38α-TAB1(371-416) in which p38α was 2 H/ 15 N/ 13 C-labeled and TAB1 unlabeled were prepared by mixture of the components in a molar ratio of 1:2 at low-micromolar concentration and concentration of the complex to 0.5 mM. The same procedure, with the inverted stoichiometric ratio, was used to prepare the NMR sample for the complex of unlabeled p38α and selectively 15 N/ 13 C-labeled TAB1(371-416).
Spectra were acquired on Bruker Avance spectrometers operating at 700 and 500 MHz ( 1 H frequency) and a Varian Inova spectrometer operating at 800 MHz, all equipped with cryoprobes. The spectra were processed with the manufacturers' software or with NMRpipe 36 , NMRViewJ 37 and XEASY 38 . The spectra were typically apodized in each dimension by application of a Gaussian or sine-bell window function and zero-filled to double the size of the data before Fourier transformation. 15 N-TROSY 39 and 13 C-HSQC 40,41 spectra were acquired in a standard manner.
Chemical-shift variations were determined by comparison of the 15 N-TROSY spectrum of free p38α with that of p38α-TAB1(371-416). The weighted average chemical-shift variation (∆δ AV ) was calculated as follows ([(∆ HN ) 2 + (∆ N ) 2 /5]/2) 1/2 , where ∆ HN and ∆ N are the chemical-shift variations in the two dimensions 42, 43 ). Chemical-shift variations were classified as being weak (∆δ A ≤0.5), strong (∆δ AV >0.5), undefined (where signals are lost upon interaction) or unclear (unassigned peaks and where spectral overlapped prevented the unambiguous analysis). The classes were mapped onto the structure of p38α (PDB 1P38, ref. 31 ).
Crystallization and structure determination. The complex of p38α-TAB1 at ~11 mg/ml preincubated with 1 mM SB220025 was crystallized by sitting-drop vapor diffusion at 4 °C. The complex crystals grew in three different conditions yielding three different forms: (i) p38α-TAB1 monoclinic, 25% w/v mediummolecular-weight PEG smears (PEG 2000, PEG 3350, PEG 4000, PEG 5000 MME), 0.1 M MES, pH 6.5; (ii) p38α-TAB1 tetragonal, 20% w/v PEG 3350, 0.2 M Na/K tartrate, 0.1 M bis-Tris propane, pH 6.5, 10% ethylene glycol; and (iii) p38α-TAB1-SO4 tetragonal, 25% w/v medium-molecular-weight PEG smears, 0.2 M ammonium sulfate, 0.01 M CdCl 2 , 0.1 M HEPES, pH 7.5. Crystals were cryoprotected with mother liquor supplemented with 20% ethylene glycol and flash cooled in liquid nitrogen. Diffraction data were collected at the Diamond Light Source, at beamline I03 for the former two crystals and I04-1 for the latter crystal, and processed and scaled with MOSFLM and SCALA from the CCP4 suite 44 . The structure was solved by molecular replacement with PHASER 45 and a p38α monomer (PDB 3QUE 46 ) as a search model. Iterative cycles of manual building alternated with structure refinement were performed with COOT 47 and REFMAC 48 , respectively. Data collection and refinement statistics are summarized in Table 2 .
Adult rat ventricular myocyte culture. ARVMs were isolated as previously described 49 and washed with M199 complete medium (M199 medium with added 100 IU/ml penicillin, 100 IU/ml streptomycin, 2 mM l-carnitine, 5 mM creatine and 5 mM taurine). The cell suspension was allowed to settle by gravity and was centrifuged at 100g for 2 min to pellet the myocytes, which were then resuspended in M199 complete medium and placed in laminin-coated six-well plates before incubation in 5% CO2/room air at 37 °C. After 1 h, the medium was aspirated, leaving only adherent cells, and fresh prewarmed M199 complete medium was added with specified TAT-TAB1 peptides.
Retrograde perfusion of isolated mouse hearts. All experiments were approved under the Animals Scientific Procedures Act, UK Home Office. After injection of intraperitoneal pentobarbital (300 mg/kg) and heparin (150 units), hearts were rapidly isolated from outbred male C57BL/6 mice (24-27g, Harlan) and placed in ice-cold modified Krebs-Henseleit buffer (KHB) (118.5 mM NaCl, 25.0 mM NaHCO 3 , 4.75 mM KCl, 1.18 mM KH 2 PO 4 , 1.19 mM MgSO 4 , 11.0 mM d-glucose and 1.4 mM CaCl 2 ). The excised hearts were mounted on a Langendorff apparatus and retrograde perfused at a constant pressure of 80 mm Hg with KHB equilibrated with 95% O2 and 5% CO 2 at 37 °C. A fluid-filled balloon inserted into the left ventricle monitored contractile function and was set to an end-diastolic pressure of 2-8 mm Hg. Atrial pacing was at 600 b.p.m. For inclusion, isolated mouse hearts after stabilization had to have a left ventricular developed pressure of at least 60 mm Hg with coronary flow between 1.5 and 3.5 ml/min while pacing at ~600 b.p.m. More-detailed methods are described in refs. 10,49.
The maximum concentration of TAT-TAB1(371-416A-B) that did not cause discernible contractile dysfunction (15 µM) was chosen as the mid-range peptide concentration. Preliminary experiments were carried out with three different concentrations of the peptide(s) to test for toxicity in the isolated heart. WT, Scr and Mut peptide and buffer controls were perfused through an isolated heart for 15 min after a 30-min baseline perfusion (n = 2 for each condition). These studies demonstrated a clear effect of WT peptide on the function of the heart in a concentration-dependent manner. Preliminary data revealed control mean LVDP = 67 mm Hg and WT peptide perfusion mean = 43 mm Hg (with an n = 2 data set) and a combined s.d. of 12 mm Hg, thus resulting in a recommended sample size of 4 < n < 6 for the concentration of peptide used in the final study, given 95% confidence and 80% probability (http://www.biomath.info/power/ ttest.htm). For the main study, peptides were randomized into falcon tubes in KH buffer and stored in a −80 °C freezer, labeled 1-28 in a random order assigned by another member of staff not involved in the perfusion protocol. Samples were taken from the freezer in order and used in the perfusion study. Hearts were exposed to 15 µM peptides, which were recirculated for 15 min in a total volume of 20 mL KHB.
Outbred C57BL/6 mice from a commercial supplier were used in this study. All mice were 8-10 weeks of age and weighed 28-31g. Blinding regarding mice was not required because the researchers' selection of mouse was unlikely to affect the outcome of the experiments.
Statistical analysis. Results are expressed as mean ± s.e.m. for hemodynamic performance of individual isolated mouse heart and mean ± s.d. for quantification of immunoblots from individual cell-transfection experiments. Data sets were analyzed by one-way (Figs. 1b,c, 5e, 6c and 6h) or two-way ( Fig. 6e,f) analysis of variance followed by Bonferroni comparison. A value of P < 0.05 was considered statistically significant.
